Recombinant Human IL-6

Catalog Number: EBT-EPT155
Article Name: Recombinant Human IL-6
Biozol Catalog Number: EBT-EPT155
Supplier Catalog Number: EPT155
Alternative Catalog Number: EBT-EPT155-50
Manufacturer: ELK Biotechnology
Category: Proteine/Peptide
Alternative Names: Interleukin-6, IL-6, B-Cell Stimulatory Factor 2, BSF-2, CTL Differentiation Factor, CDF, Hybridoma Growth Factor, Interferon Beta-2, IFN-Beta-2, IL6, IFNB2
Recombinant Human Interleukin-6 is produced by our E.coli expression system and the target gene encoding Val30-Met212 is expressed.
Molecular Weight: Molecular weight: 20.9 KDa. Apparent molecular weight: 20 KDa, reducing conditions
UniProt: P05231
Purity: Greater than 95% as determined by reducing SDS-PAGE.
Application Notes: Redissolve: Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.. Endotoxin: Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test. Biological activity: Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is 20-100 pg/ml. Background: Cytokines of the IL6/GCSF/MGF family are glycoproteins of about 170 to 180 amino acid residues that contain four conserved cysteine residues involved in two disulfide bonds. They have a compact, globular fold (similar to other interleukins), stabilized by the 2 disulfide bonds. One half of the structure is dominated by a 4 alpha-helix bundle with a left-handed twist, the helices are anti-parallel, with 2 overhand connections, which fall into a 2-stranded anti-parallel beta-sheet. The fourth alpha helix is important to the biological activity of the molecule. Interleukin-6 (IL-6) is an important proinflammatory and immunoregulatory cytokine expressed by various cells. Interleukin-6 has been shown to inhibit the growth of early stage and to promote the proliferation of advanced stage melanoma cells in vitro